Pura Vida Investments LLC Has $521,000 Holdings in Verrica Pharmaceuticals Inc (VRCA)
Pura Vida Investments LLC grew its stake in Verrica Pharmaceuticals Inc (NASDAQ:VRCA) by 219.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,916 shares of the company’s stock after buying an additional 43,916 shares during the quarter. Pura Vida Investments LLC owned approximately 0.25% of Verrica Pharmaceuticals worth $521,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently modified their holdings of VRCA. Vanguard Group Inc increased its position in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc now owns 292,489 shares of the company’s stock worth $4,753,000 after buying an additional 264,651 shares in the last quarter. Vanguard Group Inc. increased its position in Verrica Pharmaceuticals by 950.7% in the third quarter. Vanguard Group Inc. now owns 292,489 shares of the company’s stock worth $4,753,000 after buying an additional 264,651 shares in the last quarter. BlackRock Inc. purchased a new stake in Verrica Pharmaceuticals in the third quarter worth about $4,145,000. Kornitzer Capital Management Inc. KS increased its position in Verrica Pharmaceuticals by 52.2% in the fourth quarter. Kornitzer Capital Management Inc. KS now owns 327,420 shares of the company’s stock worth $2,668,000 after buying an additional 112,275 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Verrica Pharmaceuticals in the third quarter worth about $1,463,000. Institutional investors and hedge funds own 32.87% of the company’s stock.
Shares of VRCA opened at $12.90 on Friday. The stock has a market capitalization of $308.49 million and a price-to-earnings ratio of -9.15. Verrica Pharmaceuticals Inc has a 52 week low of $6.44 and a 52 week high of $23.29.
In related news, major shareholder Matt Davidson sold 25,045 shares of the stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $11.55, for a total transaction of $289,269.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Linda Palczuk bought 3,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 16th. The shares were acquired at an average price of $10.53 per share, with a total value of $31,590.00. The disclosure for this purchase can be found here. Insiders have sold 262,694 shares of company stock valued at $2,936,370 in the last quarter.
A number of analysts have commented on VRCA shares. HC Wainwright started coverage on Verrica Pharmaceuticals in a research report on Thursday, February 21st. They issued a “buy” rating and a $20.00 price target for the company. Zacks Investment Research upgraded Verrica Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, December 19th. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $26.25.
Verrica Pharmaceuticals Profile
Verrica Pharmaceuticals Inc develops and commercializes dermatological treatments in the United States. The company is advancing its lead product VP-102, a proprietary topical therapy, in various common skin indications, including Molluscum contagiosum and Verruca Vulgaris. It is also developing 2 Phase 3 trials in molluscum contagiosum under NCT03377803 and NCT03377790.
Further Reading: Buy-Side Analysts
Want to see what other hedge funds are holding VRCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Verrica Pharmaceuticals Inc (NASDAQ:VRCA).
Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.